- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | ANET |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7B | 168.2B |
| IPO Year | 1992 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | ANET |
|---|---|---|
| Price | $129.12 | $127.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 15 |
| Target Price | $128.62 | ★ $163.93 |
| AVG Volume (30 Days) | ★ 6.6M | 6.6M |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 6514.05 | 26.15 |
| EPS | ★ 6.42 | 2.63 |
| Revenue | ★ $29,087,000,000.00 | $8,448,346,000.00 |
| Revenue This Year | $3.67 | $29.44 |
| Revenue Next Year | $3.43 | $21.80 |
| P/E Ratio | ★ $19.33 | $48.49 |
| Revenue Growth | 2.79 | ★ 27.75 |
| 52 Week Low | $91.84 | $59.43 |
| 52 Week High | $128.70 | $164.94 |
Technical Indicators
Market Signals| Indicator | GILD | ANET |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 46.57 |
| Support Level | $120.95 | $120.00 |
| Resistance Level | $124.48 | $133.34 |
| Average True Range (ATR) | 3.57 | 4.87 |
| MACD | 0.57 | -0.10 |
| Stochastic Oscillator | 98.23 | 31.39 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.